Between‐Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial
Open Access
- 11 October 2016
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 101 (3), 331-340
- https://doi.org/10.1002/cpt.535
Abstract
We previously demonstrated pharmacokinetic differences among manufacturing batches of a US Food and Drug Administration (FDA)‐approved dry powder inhalation product (Advair Diskus 100/50) large enough to establish between‐batch bio‐inequivalence. Here, we provide independent confirmation of pharmacokinetic bio‐inequivalence among Advair Diskus 100/50 batches, and quantify residual and between‐batch variance component magnitudes. These variance estimates are used to consider the type I error rate of the FDA's current two‐way crossover design recommendation. When between‐batch pharmacokinetic variability is substantial, the conventional two‐way crossover design cannot accomplish the objectives of FDA's statistical bioequivalence test (i.e., cannot accurately estimate the test/reference ratio and associated confidence interval). The two‐way crossover, which ignores between‐batch pharmacokinetic variability, yields an artificially narrow confidence interval on the product comparison. The unavoidable consequence is type I error rate inflation, to ∼25%, when between‐batch pharmacokinetic variability is nonzero. This risk of a false bioequivalence conclusion is substantially higher than asserted by regulators as acceptable consumer risk (5%).Keywords
Funding Information
- Swiss State Secretariat for Education, Research, and Innovation (999754557)
This publication has 17 references indexed in Scilit:
- Pharmacokinetics, Safety, and Tolerability of a New Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate Diskus® in Healthy AdultsJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2016
- Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhalerAllergy and Asthma Proceedings, 2015
- Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose InhalerClinical Drug Investigation, 2015
- Pharmacokinetics of Orally Inhaled Drug ProductsThe AAPS Journal, 2015
- Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Generic Drug Products by the US Food and Drug AdministrationThe AAPS Journal, 2012
- Equivalence Considerations for Orally Inhaled Products for Local Action—ISAM/IPAC-RS European Workshop ReportJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2012
- British Guideline on the Management of AsthmaThorax, 2008
- Pharmacokinetics and systemic activity of fluticasone via Diskus® and pMDI, and of budesonide via Turbuhaler®British Journal of Clinical Pharmacology, 2001
- Salmeterol and fluticasone propionate given as a combinationEuropean Journal of Clinical Pharmacology, 2001
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986